{
    "medicine_id": "5cb2f4bb4d2b2069a0758f2c1f5ea5b2fe8ada43",
    "platform_id": "DB00348",
    "metadata": {
        "name": "Mdk nitisinone 2 mg Capsule",
        "composition": "2 mg Nitisinone",
        "clinical_particulars": {
            "therapeutic_indications": "Used as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1",
            "contraindications": {
                "disease": "Side effects include elevated plasma levels of this amino acid hepatic and liver failure",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Hereditary tyrosinemia type 1 occurs due to a deficiency in fumarylacetoacetase FAH the final enzyme in the tyrosine catabolic pathway Nitisinone inhibits catabolism of tyrosine by preventing the catabolic intermediates In patients with HT 1 these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate which are responsible for the observed liver and kidney toxicity Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5 aminolevulinate a neurotoxin responsible for the porphyric crises characteristic of HT 1",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}